Stéphane Hunot

Active 1996–2024

37
Papers
19,677
Citations
34
h-index
37
i10-index

Citations

Citations per year for Stéphane Hunot1971: 2 citations1992: 1 citations1996: 2 citations1997: 4 citations1998: 12 citations1999: 38 citations2000: 75 citations2001: 110 citations2002: 119 citations2003: 151 citations2004: 174 citations2005: 145 citations2006: 148 citations2007: 150 citations2008: 133 citations2009: 177 citations2010: 189 citations2011: 213 citations2012: 191 citations2013: 204 citations2014: 179 citations2015: 244 citations2016: 291 citations2017: 306 citations2018: 369 citations2019: 875 citations2020: 928 citations2021: 929 citations2022: 826 citations2023: 625 citations2024: 814 citations2025: 404 citations2026: 11 citations1972–1991: no citations, so these years are not shown1993–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,671 citing papers, 22.7% of this breakdownChina: 1,541 citing papers, 13.1% of this breakdownUnited Kingdom: 672 citing papers, 5.7% of this breakdownGermany: 608 citing papers, 5.2% of this breakdownItaly: 553 citing papers, 4.7% of this breakdownFrance: 403 citing papers, 3.4% of this breakdownSpain: 370 citing papers, 3.2% of this breakdownIndia: 368 citing papers, 3.1% of this breakdownCanada: 349 citing papers, 3% of this breakdownSouth Korea: 334 citing papers, 2.9% of this breakdownAustralia: 318 citing papers, 2.7% of this breakdownJapan: 262 citing papers, 2.2% of this breakdown
0%22.7%Other 28.1%

Fields

  • Medicine46.5%
  • Neuroscience27.2%
  • Biochemistry, Genetics and Molecular Biology18.9%
  • Immunology and Microbiology2%
  • Nursing1.3%
  • Agricultural and Biological Sciences0.9%
  • Other3.2%

Topics

  • Neuroinflammation and Neurodegeneration Mechanisms11.4%
  • Alzheimer's disease research and treatments9.6%
  • Parkinson's Disease Mechanisms and Treatments8.3%
  • Tryptophan and brain disorders3.7%
  • Nuclear Receptors and Signaling2.7%
  • Nerve injury and regeneration2.3%
  • Other62%

Coauthors

All papers

Open in search
  1. Neuroinflammation in Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Olga Garaschuk, Erik Boddeke, Charles A. Dinarello, John C.S. Breitner, Greg M. Cole, Douglas T. Golenbock, Markus P. Kummer - The Lancet Neurology 2015 cited by 6,102

  2. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease

    Authors: , , , , , , , , , , , , , - Journal of Clinical Investigation 2008 cited by 1,181

  3. Neuroinflammation in Parkinson's disease: a target for neuroprotection?

    Authors: , - The Lancet Neurology 2009 cited by 1,945

  4. Understanding Dopaminergic Cell Death Pathways in Parkinson Disease

    Authors: , , - Neuron 2016 cited by 607

  5. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

    Authors: , , , , , , , , , , , - The Lancet Neurology 2015 cited by 509

  6. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy

    Authors: , , , , , , , , , , , , , , , , , , , , - Brain 2016 cited by 288

  7. Neuroinflammation in Parkinson's disease

    Authors: , , - Parkinsonism & Related Disorders 2011 cited by 634

  8. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease

    Authors: , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 410

  9. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease

    Authors: , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2000 cited by 705

  10. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

    Authors: , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 659

  11. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease

    Authors: , , , , , , , , , , , , , - Journal of Clinical Investigation 2010 cited by 420

  12. Nitric oxide synthase and neuronal vulnerability in parkinson's disease

    Authors: , , , , , , - Neuroscience 1996 cited by 596

  13. Parkinson’s disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype

    Authors: , , , , , , , - Journal of Neuroinflammation 2024 cited by 39

  14. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease

    Authors: , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1997 cited by 683

  15. The Role of Glial Reaction and Inflammation in Parkinson's Disease

    Authors: , , , , , - Annals of the New York Academy of Sciences 2003 cited by 453

  16. Effects of oral administration of rotenone on gastrointestinal functions in mice

    Authors: , , , , , , , , , - Neurogastroenterology & Motility 2013 cited by 92

  17. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 278

  18. Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's disease

    Authors: , , , , , , - Journal of Neurochemistry 2002 cited by 117

  19. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease

    Authors: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2004 cited by 424

  20. Neuroinflammatory processes in Parkinson's disease

    Authors: , , - Parkinsonism & Related Disorders 2005 cited by 297

  21. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 cited by 238

  22. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

    Authors: , , , , , , , , , , , , , , - Scientific Reports 2013 cited by 162

  23. Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis

    Authors: , , , , , , , , - Journal of Neuroscience 2001 cited by 272

  24. Nuclear translocation of NF-κB in cholinergic neurons of patients with Alzheimerʼs disease

    Authors: , , , , , , - Neuroreport 1997 cited by 153